Navigation Links
iCo Therapeutics Closes $1.3 Million Private Placement
Date:2/9/2009

acement. All securities issued in the private placement are subject to a four month hold period. The private placement is subject to regulatory approval, including the approval of the TSX Venture Exchange.

About iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products, iCo-007, in Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies, and iCo-009, an oral formulation of Amphotericin B for sight and life - threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration. iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO". For more information, visit the company website at: www.icotherapeutics.com

    No regulatory authority has approved or disapproved the content of this
    release. The TSX Venture Exchange does not accept responsibility for the
    adequacy or accuracy of this release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial per
'/>"/>

SOURCE iCo Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
3. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
4. Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
7. Omnitura Therapeutics Announces Private Placement Financing
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. Cell Therapeutics Receives Additional NASDAQ Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - The Fight Against ... pleased to announce the formation of Turnstone Biologics ... treatments for cancer that harness the patient,s own ... unique collaboration between the Children,s Hospital of ... McMaster University, the Ontario Institute for Cancer Research ...
(Date:5/4/2015)... China Cord Blood Corporation (NYSE: CO ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has been informed that ... Hong Kong listed company and a substantial ... (the "Agreement") to purchase the Company,s outstanding 7% senior ...
(Date:5/4/2015)... May 04, 2015 Marianjoy ... patients with arm and hand impairments by acquiring ... its Oakbrook Terrace network site. , Secured through ... is a highly-regarded treatment option for patients with ... Armeo®Spring, Marianjoy becomes one of just four Illinois ...
(Date:5/1/2015)... TORONTO , May 1, 2015 /CNW/ - Softchoice, a leading ... that it is the proud recipient of two Cisco® Partner ... Services Partner of the Year and Security Partner of the ... partner conference taking place this week in Montreal ... not one, but two Cisco partner awards at this year,s ...
Breaking Biology Technology:Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2
... SAN FRANCISCO, September 23 InspireMD, developers of,MGuard(TM), ... in the,Israeli MGuard(TM) Registry. MGuard(TM) was successfully implanted in,Natanya, ... Dr. Yitzhak,Herz, the principal investigator for the Registry at ... MGuard Registry will enroll 100 ,real world, MGuard patients,from ...
... 23 Advanced Health Media LLC (AHM), the leading U.S. ... software for the pharmaceutical industry, announced that it has been ... Top Technology Innovators Across America for 2009. This is ... the country,s most innovative developers of business technology. , ...
... , , RESEARCH TRIANGLE PARK, N.C., ... a partnership with Max Healthcare to open a Phase I/IIa clinical ... proof of concept unit will allow Pharmaceutical, Biotech & Device companies ... across multiple therapeutic areas quickly and with the highest quality. , ...
Cached Biology Technology:InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco 2InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco 3Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America 2Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America 3Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America 4Max Neeman International to Open Phase I/IIa Unit 2
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Researchers at Rice University and Penn State University have ... creating nanotubes turns them into solid, spongy, reusable blocks that ... That,s one of a range of potential innovations for ... for the first time that boron puts kinks and elbows ...
... key to treating one of the most common types ... gene called FLT3, according to new research led by ... Helen Diller Family Comprehensive Cancer Center. Published this ... validates certain activating mutations in the FLT3 gene as ...
... (Boston) An international team of researchers led ... four loci that appear to be associated with decreasing ... region of the brain that plays an important role ... an ability that patients with Alzheimer,s disease lose. The ...
Cached Biology News:Nanosponges soak up oil again and again 2Nanosponges soak up oil again and again 3An Achilles heel of AML 2An Achilles heel of AML 3BUSM researchers identify genes that influence hippocampal volume 2